• 1
    Yelin E. The economics of osteoarthritis. In: BrandtKD, DohertyM, LohmanderLS, editors. Osteoarthritis. 2nd ed. Oxford: Oxford University Press; 2003. p. 1721.
  • 2
    Brandt KD, Mazzuca SA. Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs [review]. Arthritis Rheum 2005; 52: 334959.
  • 3
    Conaghan PG, Felson D, Gold G, Lohmander S, Totterman S, Altman R. MRI and non-cartilaginous structures in knee osteoarthritis. Osteoarthritis Cartilage 2006; 14 Suppl A: A8794.
  • 4
    Garnero P, Rousseau JC, Delmas PD. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases [review]. Arthritis Rheum 2000; 43: 95368.
  • 5
    Kraus VB. Biomarkers in osteoarthritis. Curr Opin Rheumatol 2005; 17: 6416.
  • 6
    Schaller S, Henriksen K, Hoegh-Andersen P, Sondergaard BC, Sumer EU, Tanko LB, et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 2005; 3: 55380.
  • 7
    Thonar EJ, Masuda K, Manicourt DH, Kuettner KE. Structure and function of normal human adult articular cartilage. In: ReginsterJY, PelletierJP, PelletierJ, HenrotinY, editors. Osteoarthritis: clinical and experimental aspects. Berlin: Springer-Verlag; 1999. p. 119.
  • 8
    Sugiyama S, Itokazu M, Suzuki Y, Shimizu K. Procollagen II C propeptide level in the synovial fluid as a predictor of radiographic progression in early knee osteoarthritis. Ann Rheum Dis 2003; 62: 2732.
  • 9
    Nelson F, Dahlberg L, Laverty S, Reiner A, Pidoux I, Ionescu M, et al. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 1998; 102: 211525.
  • 10
    Hollander AP, Pidoux I, Reiner A, Rorabeck C, Bourne R, Poole AR. Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. J Clin Invest 1995; 96: 285969.
  • 11
    Hollander AP, Heathfield TF, Webber C, Iwata Y, Bourne R, Rorabeck C, et al. Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest 1994; 93: 172232.
  • 12
    Hollander AP, Heathfield TF, Liu JJ, Pidoux I, Roughley PJ, Mort JS, et al. Enhanced denaturation of the α (II) chains of type-II collagen in normal adult human intervertebral discs compared with femoral articular cartilage. J Orthop Res 1996; 14: 616.
  • 13
    Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997; 99: 153445.
  • 14
    Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G. Biochemical characterization of human collagenase-3. J Biol Chem 1996; 271: 154450.
  • 15
    Neuhold LA, Killar L, Zhao W, Sung ML, Warner L, Kulik J, et al. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J Clin Invest 2001; 107: 3544.
  • 16
    Wu W, Billinghurst RC, Pidoux I, Antoniou J, Zukor D, Tanzer M, et al. Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. Arthritis Rheum 2002; 46: 208794.
  • 17
    Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001; 29: 20915.
  • 18
    Charni N, Juillet F, Garnero P. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2005; 52: 108190.
  • 19
    Deberg M, Labasse A, Christgau S, Cloos P, Bang HD, Chapelle JP, et al. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2005; 13: 25865.
  • 20
    Jordan KM, Syddall HE, Garnero P, Gineyts E, Dennison EM, Sayer AA, et al. Urinary CTX-II and glucosyl-galactosyl-pyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men. Ann Rheum Dis 2006; 65: 8717.
  • 21
    Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC. The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods 2004; 294: 14553.
  • 22
    Chu Q, Lopez M, Hayashi K, Ionescu M, Billinghurst RC, Johnson KA, et al. Elevation of a collagenase generated type II collagen neoepitope and proteoglycan epitopes in synovial fluid following induction of joint instability in the dog. Osteoarthritis Cartilage 2002; 10: 6629.
  • 23
    Lu Y, Markel MD, Swain C, Kaplan LD. Development of partial thickness articular cartilage injury in an ovine model. J Orthop Res 2006; 24: 197482.
  • 24
    Huebner JL, Kraus VB. Assessment of the utility of biomarkers of osteoarthritis in the guinea pig. Osteoarthritis Cartilage 2006; 14: 92330.
  • 25
    Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 2006; 54: 320511.
  • 26
    King KB, Lindsey CT, Dunn TC, Ries MD, Steinbach LS, Majumdar S. A study of the relationship between molecular biomarkers of joint degeneration and the magnetic resonance-measured characteristics of cartilage in 16 symptomatic knees. Magn Reson Imaging 2004; 22: 111723.
  • 27
    Mazzuca SA, Poole AR, Brandt KD, Katz BP, Lane KA, Lobanok T. Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis. J Rheumatol 2006; 33: 114751.
  • 28
    Deberg MA, Labasse AH, Collette J, Seidel L, Reginster JY, Henrotin YE. One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cartilage 2005; 13: 105965.
  • 29
    Garnero P, Charni N, Juillet F, Conrozier T, Vignon E. Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis. Ann Rheum Dis 2006; 65: 163944.
  • 30
    Ameye LG, Young MF. Animal models of osteoarthritis: lessons learned while seeking the “Holy Grail.” Curr Opin Rheumatol 2006; 18: 53747.
  • 31
    Ameye L, Aria D, Jepsen K, Oldberg A, Xu T, Young MF. Abnormal collagen fibrils in tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis. FASEB J 2002; 16: 67380.
  • 32
    Wadhwa S, Embree MC, Kilts T, Young MF, Ameye LG. Accelerated osteoarthritis in the temporomandibular joint of biglycan/fibromodulin double-deficient mice. Osteoarthritis Cartilage 2005; 13: 81727.
  • 33
    Ameye L, Young MF. Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology 2002; 12: 10716R.
  • 34
    Quasnichka HL, Anderson-MacKenzie JM, Tarlton JF, Sims TJ, Billingham ME, Bailey AJ. Cruciate ligament laxity and femoral intercondylar notch narrowing in early-stage knee osteoarthritis. Arthritis Rheum 2005; 52: 31009.
  • 35
    Xu T, Bianco P, Fisher L, Longenecker G, Smith E, Goldstein S, et al. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet 1998; 20: 7882.
  • 36
    Svensson L, Aszodi A, Reinholt F, Fassler R, Heinegard D, Oldberg A. Fibromodulin-null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon. J Biol Chem 1999; 274: 963647.
  • 37
    Li CY, Ziesmer SC, Lazcano-Villareal O. Use of azide and hydrogen peroxide as an inhibitor for endogenous peroxidase in the immunoperoxidase method. J Histochem Cytochem 1987; 35: 145760.
  • 38
    Halloran BP, Ferguson VL, Simske SJ, Burghardt A, Venton LL, Majumdar S. Changes in bone structure and mass with advancing age in the male C57BL/6J mouse. J Bone Miner Res 2002; 17: 104450.
  • 39
    Embry JJ, Knudson W. G1 domain of aggrecan cointernalizes with hyaluronan via a CD44-mediated mechanism in bovine articular chondrocytes. Arthritis Rheum 2003; 48: 343141.
  • 40
    Embry Flory JJ, Fosang AJ, Knudson W. The accumulation of intracellular ITEGE and DIPEN neoepitopes in bovine articular chondrocytes is mediated by CD44 internalization of hyaluronan. Arthritis Rheum 2006; 54: 44354.